Vertex Pharmaceuticals Receives FDA's Orphan Designation For Atumelnant To Treat Endogenous Cushing’s Syndrome

뉴스 본문을 불러오고 있어요.

Vertex Pharmaceuticals Receives FDA's Orphan Designation For Atumelnant To Treat Endogenous Cushing’s Syndrome | 웨이프 WAPE

기사 요약